Hirotsugu Honzyo

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease

Junichi Yamaguchi, Hiroyuki Arashi, Nobuhisa Hagiwara, Satoshi Yasuda et autres

Importance: Antithrombotic therapy is crucial for older patients with coronary artery disease (CAD) and atrial fibrillation (AF) who are at a high risk of bleeding and thrombotic events. Objective: To examine the age-stratified effects of rivaroxaban monotherapy compared with those of rivaroxaban …

jp (code pays fourni par la source)

Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease

Ryo Naito, Katsumi Miyauchi, Satoshi Yasuda, Koichi Kaikita et autres

Importance: Appropriate regimens of antithrombotic therapy for patients with atrial fibrillation (AF) and coronary artery disease (CAD) have not yet been established. Objective: To compare the total number of thrombotic and/or bleeding events between rivaroxaban monotherapy and combined rivaroxaban and antiplatelet therapy …

jp (code pays fourni par la source)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting

Tetsuya Matoba, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao et autres

jp (code pays fourni par la source)